Skip to main content

MREO

Stock
Health Care
Biotechnology

Performance overview

MREO Price
Price Chart

Forward-looking statistics

Beta
0.88
Risk
62.99%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Company info

SectorHealth Care
IndustryBiotechnology
Employees34
Market cap$479.7M

Fundamentals

Enterprise value$2.1B
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity1.24

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.35
Dividend per share
Revenue per share
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth-0.8
Credit+9.5
Liquidity-0.1
Inflation-7.0
Commodities-5.1
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-95.67
Price to sales
P/E Ratio-95.67
Enterprise Value to Revenue
Price to book7.59

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

Zacks Investment Research (July 10, 2025)
Why Mereo BioPharma Shares Are Jumping Today

AstraZeneca plc (NASDAQ: AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ: MREO), according to a report in The Times. The Times' report says that "Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs.

Benzinga (June 17, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free